Author Response

Authors' Response

Authors: David F. Archer, MD

Abstract

To the Editor: In his letter to the editor, Quinton points out the problem of using high levels of estrogen for long periods of time in men who have undergone gender reassignment surgery. These individuals appear to be at a high risk for myocardial infarction, and yet the Women’s Health Initiative (WHI) has not found an increased incidence of myocardial infarction in young postmenopausal women using conjugated estrogen (CE; Premarin, Pfizer), with or without medroxyprogesterone acetate, which is a synthetic progestin.1-3 One question addresses whether there is a difference between CE and estradiol (E2), the endogenous estrogen secreted by the ovaries and testes and found in the peripheral blood of both men and women when used in postmenopausal women.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. LaCroix AZ, Chlebowski RT, Manson JE, et al. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA 2011;305:1305-1314.
 
2. Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA 2013;310:1353-1368.
 
3. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297: 1465-1477.
 
4. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999;340:1801-1811.
 
5. Clarkson TB. Estrogen effects on arteries vary with stage of reproductive life and extent of subclinical atherosclerosis progression. Menopause 2007;14(3 Pt 1): 373-384.
 
6. Harman SM, Black DM, Naftolin F, et al. Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial. Ann Intern Med 2014;161:249-260.
 
7. Hodis HN, Mack WJ. Hormone replacement therapy and the association with coronary heart disease and overall mortality: clinical application of the timing hypothesis. J Steroid Biochem Mol Biol 2014;142:68-75.
 
8. Coronary Drug Project. Findings leading to discontinuation of the 2.5-mg day estrogen group. The Coronary Drug Project Research Group. JAMA 1973;226:652-657.
 
9. Phillips GB, Castelli WP, Abbott RD, et al. Association of hyperestrogenemia and coronary heart disease in men in the Framingham cohort. Am J Med 1983;74:863-869.
 
10. Phillips GB. Evidence for hyperoestrogenaemia as a risk factor for myocardial infarction in men. Lancet 1976;2:14-18.
 
11. Phillips GB. Is atherosclerotic cardiovascular disease an endocrinological disorder? The estrogen-androgen paradox. J Clin Endocrinol Metab 2005;90:2708-2711.